developed a novel anti‐tumor method by delivering antigens to the tumor surface using the antibody peptide epitope conjugate (APEC), thus guiding CMV‐specific CD8+ T cells for targeted killing.[212] Furthermore, bispecific antibodies that target neoantigens using tumor‐specific mutants predicted by computers have been synthesized to directionally kill tumor cells. This evidence concerns the gene CD8A and neoplasm.